Here we demonstrate the therapeutic efficacy of CASQ2 gene therapy in human cardiac myocytes derived from a CPVT patient presenting with a severe clinical phenotype and a radical mutation (frameshift leading to premature truncation). This evidence concerns the gene CASQ2 and catecholaminergic polymorphic ventricular tachycardia.